B-Cell Depletion Extends the Survival of GTKO.hCD46Tg Pig Heart Xenografts in Baboons for up to 8 Months

被引:126
作者
Mohiuddin, M. M. [1 ]
Corcoran, P. C. [1 ]
Singh, A. K. [1 ]
Azimzadeh, A. [4 ]
Hoyt, R. F., Jr. [2 ]
Thomas, M. L. [3 ]
Eckhaus, M. A. [3 ]
Seavey, C. [1 ]
Ayares, D. [5 ]
Pierson, R. N., III [4 ]
Horvath, K. A. [1 ]
机构
[1] NHLBI, Cardiothorac Surg Res Program, NIH, Bethesda, MD 20892 USA
[2] NHLBI, LAMS, NIH, Bethesda, MD 20892 USA
[3] NIH, DVR, ORS, Bethesda, MD 20892 USA
[4] Univ Maryland, Sch Med, Baltimore, MD 21201 USA
[5] Revivicor Inc, Blacksburg, VA USA
关键词
anti-CD20; B-cell depletion; CD46; transgenic; complement; Gal knockout pigs; xenoantibody; Xenograft; GENE-KNOCKOUT PIGS; HYPERACUTE REJECTION; CLINICAL XENOTRANSPLANTATION; TRANSGENIC PIG; TRANSPLANTATION; PRIMATES; PROGRESS; MODEL;
D O I
10.1111/j.1600-6143.2011.03846.x
中图分类号
R61 [外科手术学];
学科分类号
摘要
Xenotransplantation of genetically modified pig organs offers great potential to address the shortage of human organs for allotransplantation. Rejection in Gal knockout (GTKO) pigs due to elicited non-Gal antibody response required further genetic modifications of donor pigs and better control of the B-cell response to xenoantigens. We report significant prolongation of heterotopic alpha Galactosyl transferase knock-out and human CD46 transgenic (GTKO.hCD46Tg) pig cardiac xenografts survival in specific pathogen free baboons. Peritransplant B-cell depletion using 4 weekly doses of anti-CD20 antibody in the context of an established ATG, anti-CD154 and MMF-based immunosuppressive regimen prolonged GTKO.hCD46Tg graft survival for up to 236 days (n = 9, median survival 71 days and mean survival 94 days). B-cell depletion persisted for over 2 months, and elicited anti-non-Gal antibody production remained suppressed for the duration of graft follow-up. This result identifies a critical role for B cells in the mechanisms of elicited anti-non-Gal antibody and delayed xenograft rejection. Model-related morbidity due to variety of causes was seen in these experiments, suggesting that further therapeutic interventions, including candidate genetic modifications of donor pigs, may be necessary to reduce late morbidity in this model to a clinically manageable level.
引用
收藏
页码:763 / 771
页数:9
相关论文
共 22 条
[1]   Human membrane cofactor protein (MCP, CD 46) protects transgenic pig hearts from hyperacute rejection in primates [J].
Adams, DH ;
Kadner, A ;
Chen, RH ;
Farivar, RS .
XENOTRANSPLANTATION, 2001, 8 (01) :36-40
[2]   Left ventricular device as destination therapy: are we there yet? [J].
Badiwala, Mitesh V. ;
Rao, Vivek .
CURRENT OPINION IN CARDIOLOGY, 2009, 24 (02) :184-189
[3]   Clinical xenotransplantation [J].
Chapman, LE ;
Bloom, ET .
JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 2001, 285 (18) :2304-2306
[4]   Recent advances in pig-to-human organ and cell transplantation [J].
Cooper, David K. C. ;
Ezzelarab, Mohamed ;
Hara, Hidetaka ;
Ayares, David .
EXPERT OPINION ON BIOLOGICAL THERAPY, 2008, 8 (01) :1-4
[5]   Surgical and Nonsurgical Complications of a Pig to Baboon Heterotopic Heart Transplantation Model [J].
Corcoran, P. C. ;
Horvath, K. A. ;
Singh, A. K. ;
Hoyt, R. F., Jr. ;
Thomas, M. L., III ;
Eckhaus, M. A. ;
Mohiuddin, M. M. .
TRANSPLANTATION PROCEEDINGS, 2010, 42 (06) :2149-2151
[6]   Xenotransplantation - current status and future perspectives [J].
Cozzi, Emanuele ;
Bosio, Erika ;
Seveso, Michela ;
Vadori, Marta ;
Ancona, Ermanno .
BRITISH MEDICAL BULLETIN, 2005, 75-76 :99-114
[7]   On the road to clinical xenotransplantation [J].
Cozzi, Emanuele .
TRANSPLANT IMMUNOLOGY, 2009, 21 (02) :57-59
[8]  
Daniels LJ, 1997, KIDNEY INT, pS28
[9]   Therapeutic issues in the treatment of vascularized xenotransplants using gal-knockout donors in nonhuman primates [J].
Ekser, Burcin ;
Kumar, Goutham ;
Veroux, Massimiliano ;
Cooper, David K. C. .
CURRENT OPINION IN ORGAN TRANSPLANTATION, 2011, 16 (02) :222-230
[10]   Heart transplantation in baboons using 1,3-galactosyl transferase gene-knockout pigs as donors: initial experience [J].
Kuwaki, K ;
Tseng, YL ;
Dor, FJMF ;
Shimizu, A ;
Houser, SL ;
Sanderson, TM ;
Lancos, CJ ;
Prabharasuth, DD ;
Cheng, J ;
Moran, K ;
Hisashi, Y ;
Mueller, N ;
Yamada, K ;
Greenstein, JL ;
Hawley, RJ ;
Patience, C ;
Awwad, M ;
Fishman, JA ;
Robson, SC ;
Schuurman, HJ ;
Sachs, DH ;
Cooper, DKC .
NATURE MEDICINE, 2005, 11 (01) :29-31